TrialBMC endocrine disorders2025

The effect of empagliflozin on non-alcoholic fatty liver disease-related parameters in patients with type 2 diabetes mellitus: a randomized controlled trial.

Fatemeh Shojaei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.